Ethell, Iryna Archives

Combining Gene Reactivation with Controlled Sound Exposure to Treat Fragile X Syndrome

March 11, 2025

The team combined gene reactivation with noninvasive acoustic stimulation in a mouse model as an approach to treating Fragile X syndrome.

Reactivating the Fragile X Gene in Young Mice Reverses Symptoms

December 28, 2021

Fragile X syndrome might be treated by reactivating the gene which is shut down in the syndrome. Researchers were able to reduce FXS symptoms by inserting the FMR1 gene into the brains of young mice.

Cholesterol-Dependent Changes in Fragile X Astrocytes

May 6, 2020

Astrocytes and cholesterol metabolism are altered in Fragile X. This research uncovers how these changes affect the brain and may reveal new treatment targets like lovastatin.

Devon Binder, PhD; Iryna Ethell, PhD, Patricia Pirbhoy, PhD, at UC Riverside School of Medicine

Understanding and Reversing Hypersensitivity to Sounds in Fragile X Syndrome

June 20, 2018

This FRAXA grant studied why people with Fragile X are overly sensitive to sound and tested drug strategies to calm the brain’s overactive auditory circuits.

Iryna Ethell UC Riverside, FRAXA researcher

Fragile X Syndrome Treatment Target: MMP-9

July 24, 2014

This paper shows that MMP-9 dysregulation is a critical part of the pathology of Fragile X, and MMP-9 should be considered a major treatment target for Fragile X syndrome.

Effects of minocycline on vocal production and auditory processing in a mouse model of Fragile X

June 2, 2013

With FRAXA funding, Dr. Khaleel Razak and Dr. Iryna Ethell explored robust biomarkers relevant to the FXS and the efficacy of minocycline treatment.

Iryna Ethell, PhD, at University of California

Role of Matrix Metalloproteinases (MMP-9) in Fragile X

February 2, 2009

With a $220,000 FRAXA grant, Dr. Iryna Ethell’s team at UC Riverside uncovered MMP-9’s role in Fragile X—leading to a major treatment strategy using minocycline.

Combining Gene Reactivation with Controlled Sound Exposure to Treat Fragile X Syndrome

Reactivating the Fragile X Gene in Young Mice Reverses Symptoms

Cholesterol-Dependent Changes in Fragile X Astrocytes

Understanding and Reversing Hypersensitivity to Sounds in Fragile X Syndrome

Fragile X Syndrome Treatment Target: MMP-9

Effects of minocycline on vocal production and auditory processing in a mouse model of Fragile X

Role of Matrix Metalloproteinases (MMP-9) in Fragile X

Support FRAXA

Get In Touch!

Explore Fragile X & Research

Get FRAXA Updates